The historical rank and industry rank for Swedish Orphan Biovitrum AB's Cyclically Adjusted Price-to-FCF or its related term are showing as below:
LTS:0MTD'
s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 61.25 Med: 152.14 Max: 1493.89
Current: 73.35
During the past years, Swedish Orphan Biovitrum AB's highest Cyclically Adjusted Price-to-FCF was 1493.89. The lowest was 61.25. And the median was 152.14.
LTS:0MTD's Cyclically Adjusted Price-to-FCF is ranked worse than 77.23% of 325
companies
in the Drug Manufacturers industry
Industry Median: 31.58
vs LTS:0MTD: 73.35
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
Swedish Orphan Biovitrum AB's adjusted free cash flow per share data for the three months ended in Mar. 2025 was kr6.583. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is kr4.15 for the trailing ten years ended in Mar. 2025.
Shiller PE for Stocks: The True Measure of Stock Valuation
Swedish Orphan Biovitrum AB Cyclically Adjusted Price-to-FCF Historical Data
The historical data trend for Swedish Orphan Biovitrum AB's Cyclically Adjusted Price-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Swedish Orphan Biovitrum AB Cyclically Adjusted Price-to-FCF Chart
Competitive Comparison of Swedish Orphan Biovitrum AB's Cyclically Adjusted Price-to-FCF
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's Cyclically Adjusted Price-to-FCF falls into.
Swedish Orphan Biovitrum AB Cyclically Adjusted Price-to-FCF Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Swedish Orphan Biovitrum AB (LTS:0MTD) Cyclically Adjusted Price-to-FCF Explanation
Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.
Swedish Orphan Biovitrum AB Cyclically Adjusted Price-to-FCF Related Terms
Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTS:0MTD has been successfully added to your 